Brucellosis: The case for live, attenuated vaccines

Vaccine

Volumn 27, Issue SUPPL. 4, 2009, Pages

  Ficht, Thomas A ^a   Kahl McDonagh, Melissa M ^a   Arenas Gamboa, Angela M ^a,b   Rice Ficht, Allison C ^a,b  

^a TEXAS A AND M UNIVERSITY   (United States)

^b TEXAS A M COLLEGE OF MEDICINE   (United States)

Author keywords

Brucella; Microencapsulation; Mutants; Vaccines

Indexed keywords

BRUCELLA VACCINE; DOXYCYCLINE; GENTAMICIN; LIVE VACCINE; RIFAMPICIN; STREPTOMYCIN; TETRACYCLINE;

ARTICLE; BRUCELLOSIS; DISEASE FREE SURVIVAL; DRUG DELIVERY SYSTEM; DRUG DESIGN; DRUG EFFICACY; DRUG SAFETY; GENE DELETION; HUMAN; IMMUNE RESPONSE; IMMUNOSTIMULATION; NONHUMAN; PRIORITY JOURNAL;

EID: 77951234756     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2009.08.058     Document Type: Article

References (87)

1. Pappas G, Papadimitriou P, Akritidis N, Christou L, Tsianos E. The new global map of human brucellosis. Lancet Infect Dis 2006;6(2):91-9.
2. Alausa O.K., Corbel M.J., Elberg S.S., Gargani G., Gubina E.A., Shi-Lang L. et al, AT Joint FAO/WHO expert committee on brucellosis, World Health Organization Technical Report Series, 740, January, 1986, 1-132.
3. Corbel MJ. Brucellosis: an overview. Emerg Infect Dis 1997;3(January (2)):213-21.
4. Pappas G, Akritidis N, Bosilkovski M, Tsianos E, Brucellosis. N Engl J Med 2005;352(June (22)):2325-36.
5. Radwan AI, Bekairi SI, al-Bokmy AM, Prasad PV, Mohamed OM, Hussain ST. Successful therapeutic regimens for treating Brucella melitensis and Brucella abortus infections in cows. Rev-Off Int Epizoot 1993;12(September (3)):909-22.
6. Nicoletti P, Lenk RP, Popescu MC, Swenson CE. Efficacy of various treatment regimens, using liposomal streptomycin in cows with brucellosis. Am J Vet Res 1989;50(July (7)):1004-7.
7. Nicoletti P, Milward FW, Hoffmann E, Altvater L. Efficacy of long-acting oxytetracycline alone or combined with streptomycin in the treatment of bovine brucellosis. J Am Vet Med Assoc 1985;187(September (5)):493-5.
8. Milward FW, Nicoletti P, Hoffmann E. Effectiveness of various therapeutic regimens for bovine brucellosis. Am J Vet Res 1984;45(September (9)):1825-8.
9. Smith RA, Thedford TR, Espe BH, Woodson PD, Burrows GE. Effect of oxytetracycline administration on antibody response to Brucella abortus vaccination in calves. J Am Vet Med Assoc 1983;183(July (1)):70-1.
10. Fensterbank R. Oxytetracycline treatment of cows with long-standing brucellosis. Ann Rech Vet 1976;7(January (3)):231-40.
11. Gutschmidt HJ, Benndorf S. Contribution to the antibiotic therapy of Brucella abortus. Therapie der Gegenwart 1968;107(March (3)):389-90 [passim].
12. Turkmani A, Ioannidis A, Christidou A, Psaroulaki A, Loukaides F, Tselentis Y. In vitro susceptibilities of Brucella melitensis isolates to eleven antibiotics. Ann Clin Microbiol Antimicrob 2006;5(January):24.
13. Pappas G, Papadimitriou P, Christou L, Akritidis N. Future trends in human brucellosis treatment. Expert Opin Investig Drugs 2006;15(October (10)):1141-9.
14. Brouillard JE, Terriff CM, Tofan A, Garrison MW. Antibiotic selection and resistance issues with fluoroquinolones and doxycycline against bioterrorism agents. Pharmacotherapy 2006;26(January (1)):3-14.
15. Al Dahouk S, Hagen RM, Nockler K, Tomaso H, Wittig M, Scholz HC, et al. Failure of a short-term antibiotic therapy for human brucellosis using ciprofloxacin. A study on in vitro susceptibility of Brucella strains. Chemotherapy 2005;51(October (6)):352-6.
16. Pappas G, Seitaridis S, Akritidis N, Tsianos E. Treatment of Brucella spondylitis: lessons from an impossible meta-analysis and initial report of efficacy of a fluoroquinolone-containing regimen. Int J Antimicrob Agents 2004;24(November (5)):502-7.
17. Lecároz C, Blanco-Prieto MJ, Burrell MA, Gamazo C. Intracellular killing of Brucella melitensis in human macrophages with microsphere-encapsulated gentamicin. J Antimicrob Chemother 2006;58(September (3)):549-56.
18. Vershilova PA. The use of live vaccine for vaccination of human beings against brucellosis in the USSR. Bull World Health Organ 1961;24:85-9.
19. Davis DS, Elzer PH. Brucella vaccines in wildlife. Vet Microbiol 2002;90(December (1-4)):533-44.
20. Schurig GG, Sriranganathan N, Corbel MJ. Brucellosis vaccines: past, present and future. Vet Microbiol 2002;90(December (1-4)):479-96.
21. Zhao Z, Li M, Luo D, Xing L, Wu S, Duan Y, et al. Protection of mice from Brucella infection by immunization with attenuated Salmonellaenterica serovar typhimurium expressing A L7/L12 and BLS fusion antigen of Brucella. Vaccine 2009;(July).
22. Pasquevich KA, Estein SM, García Samartino C, Samartino CG, Zwerdling A, Coria LM, et al. Immunization with recombinant Brucella species outer membrane protein Omp16 or Omp19 in adjuvant induces specific CD4+ and CD8+ T cells as well as systemic and oral protection against Brucella abortus infection. Infect Immun 2009;77(January (1)):436-45.
23. Pakzad I, Rezaee A, Rasaee MJ, Tabbaraee B, Delpisheh A. Immunogencity of HSA-L7/L12 (Brucella abortus ribosomal protein) in an animal model. Iran J Immunol 2009;6(March (1)):12-21.
24. Harms JS, Durward MA, Magnani DM, Splitter GA. Evaluation of recombinant invasive, non-pathogenic Eschericia coli as a vaccine vector against the intracellular pathogen, Brucella. Journal of immune based therapies and vaccines 2009;7(January):1.
25. González M, Andrews E, Folch H, Sáez D, Cabrera A, Salgado P, et al. Cloning, expression and immunogenicity of the translation initiation factor 3 homologue of Brucella abortus. Immunobiology 2009;214(January (2)):113-20.
26. Hu XD, Yu DH, Chen ST, Li SX, Cai H. A combined DNA vaccine provides protective immunity against Mycobacterium bovis and Brucella abortus in cattle. DNA Cell Biol 2009;28(April (4)):191-9.
27. Hoz L, Cambero MI, Cabeza MC, Herrero AM, Ordónez JA. Elimination of Listeria monocytogenes from vacuum-packed dry-cured ham by E-beam radiation. J Food Protect 2008;71(October (10)):2001-6.
28. Chalise PR, Hotta E, Matak KE, Jaczynski J. Inactivation kinetics of Escherichia coli by pulsed electron beam. J Food Sci 2007;72(September (7)):M280-5.
29. Kahl-McDonaghMM, Arenas-Gamboa AM, Ficht TA. Aerosol infection of BALB/c mice with Brucella melitensis and Brucella abortus and protective efficacy against aerosol challenge. Infect Immun 2007;75(10):4923-32.
30. Bossi P, Tegnell A, Baka A, Van Loock F, Hendriks J, Werner A, et al. Bichat guidelines for the clinical management of brucellosis and bioterrorism-related brucellosis. Euro Surveill 2004;9(December (12)):E15-6.
31. Elberg SS, Faunce Jr WK. Immunization against Brucella infection: VIII. The response of Cynomolgus philippinensis. Guinea pigs and pregnant goats to infection by the Rev-1 strain of Brucella melitensis. Bull World Health Org 1962;26:421-36.
32. Buck JM. Studies of vaccination during calfhood to prevent bovine infectious abortion. J Agric Res 1930;41:667-89.
33. Allen CA, Adams LG, Ficht TA. Transposon-derived Brucella abortus rough mutants are attenuated and exhibit reduced intracellular survival. Infect Immun 1998 Mar 6;66(3):1008-16.
34. Foulongne V, Bourg G, Cazevieille C, Michaux-Charachon S, O'Callaghan D. Identification of Brucella suis genes affecting intracellular survival in an in vitro human macrophage infection model by signature-tagged transposon mutagenesis. Infect Immun 2000;68(March (3)):1297-303.
35. Delrue RM, Martinez-Lorenzo M, Lestrate P, Danese I, Bielarz V, Mertens P, et al. Identification of Brucella spp. genes involved in intracellular trafficking. Cell Microbiol 2001;3(July (7)):487-97.
36. Kim S, Watarai M, Kondo Y, Erdenebaatar J, Makino S, Shirahata T. Isolation and characterization of mini-Tn5Km2 insertion mutants of Brucella abortus deficient in internalization and intracellular growth in HeLa cells. Infect Immun 2003;71(June (6)):3020-7.
37. Lestrate P, Dricot A, Delrue RM, Lambert C, Martinelli V, De Bolle X, et al. Attenuated signature-tagged mutagenesis mutants of Brucella melitensis identified during the acute phase of infection in mice. Infect Immun 2003;71(December (12)):7053-60.
38. Kohler S, Foulongne V, Ouahrani-Bettache S, Bourg G, Teyssier J, Ramuz M, et al. The analysis of the intramacrophagic virulome of Brucella suis deciphers the environment encountered by the pathogen inside the macrophage host cell. Proc Natl Acad Sci USA 2002;99(November (24)):15711-6.
39. Fiorentino MA, Campos E, Cravero SL, Arese AI, Paolicchi F, Campero C, et al. Protection levels in vaccinated heifers with experimental vaccines Brucella abortus M1-luc and INTA 2. Vet Microbiol 2008;132(December (3-4)):302-11.
40. Edmonds M, Booth N, Hagius S, Walker J, Enright F, Martin Roop R, et al. Attenuation and immunogenicity of a Brucella abortus htrA cycL double mutant in cattle. Vet Microbiol 2000;76(1):81-90.
41. van der Lubben IM, Verhoef JC, Borchard G, Junginger HE. Chitosan for mucosal vaccination. Adv Drug Deliv Rev 2001;52(November (2)):139-44.
42. Apicella C, Custidiano A, Miranda S, NovoaL, Dokmetjian J, Gentile T. Differential macrophage modulation of asymmetric IgG antibody synthesis by soluble or particulate stimuli. Immunol Lett 2006;103(March (2)):177-85.
43. Manocha M, Pal PC, Chitralekha KT, Thomas BE, Tripathi V, Gupta SD, et al. Enhanced mucosal and systemic immune response with intranasal immunization of mice with HIV peptides entrapped in PLG microparticles in combination with Ulex Europaeus-I lectin as M cell target. Vaccine 2005;23(December (48-49)):5599-617.
44. Zhu B, Qie Y, Wang J, Zhang Y, Wang Q, Xu Y, et al. Chitosan microspheres enhance the immunogenicity of an Ag85B-based fusion protein containing multiple T-cell epitopes of Mycobacterium tuberculosis. European journal of pharmaceutics and biopharmaceutics: official journal of Arbeitsgemeinschaft für Pharmazeutische Verfahrenstechnik eV 2007;66(June (3)):318-26.
45. Grilló MJ, Marín CM, Barberán M, De Miguel MJ, Laroucau K, Jacques I, et al. Efficacy of bp26 and bp26/omp31 B. melitensis Rev. 1 deletion mutants against Brucella ovis in rams. Vaccine 2009;27(January (2)):187-91.
46. Barrio MB, Grilló MJ, Mu{ogonek}noz PM, Jacques I, González D, de Miguel MJ, et al. Rough mutants defective in core and O-polysaccharide synthesis and export induce antibodies reacting in an indirect ELISA with smooth lipopolysaccharide and are less effective than Rev 1 vaccine against Brucella melitensis infection of sheep. Vaccine 2009;27(March (11)):1741-9.
47. Pei J, Wu Q, Kahl-McDonagh M, Ficht TA. Cytotoxicity in macrophages infected with rough Brucella mutants is type IV secretion system dependent. Infect Immun 2008;76(January (1)):30-7.
48. Billard E, Dornand J, Gross A. VirB type IV secretory system does not contribute to Brucella suis avoidance of human dendritic cell maturation. FEMS Immunol Med Microbiol 2008;53(August (3)):404-12.
49. Sangari FJ, Seoane A, Rodríguez MC, Agüero J, García Lobo JM. Characterization of the urease operon of Brucella abortus and assessment of its role in virulence of the bacterium. Infect Immun 2007;75(Feburary (2)):774-80.
50. Dozot M, Boigegrain RA, Delrue RM, Hallez R, Ouahrani-Bettache S, Danese I, et al. The stringent response mediator Rsh is required for Brucella melitensis and Brucella suis virulence, and for expression of the type IV secretion system virB. Cell Microbiol 2006;8(June (11)):1791-802.
51. Kahl-McDonagh MM, Elzer PH, Hagius SD, Walker JV, Perry QL, Seabury CM, et al. Evaluation of novel Brucella melitensis unmarked deletion mutants for safety and efficacy in the goat model of brucellosis. Vaccine 2006;24(June (24)):5169-77.
52. Elzer PH, Hagius SD, Davis DS, DelVecchio VG, Enright FM. Characterization of the caprine model for ruminant brucellosis. Vet Microbiol 2002;90(December (1-4)):425-31.
53. MenseMG, Borschel RH, Wilhelmsen CL, Pitt ML, Hoover DL. Pathologic changes associated with brucellosis experimentally induced by aerosol exposure in rhesus macaques (Macaca mulatta). Am J Vet Res 2004;65(May (5)):644-52.
54. Chen TH, Elberg SS. Priming of Macaca cynomolgus philippinensis with purified antigen of Brucella melitensis before injection of Rev. I vaccine. J Infect Dis 1976;134(September (3)):294-6.
55. Chen TH, Elberg SS. Immunization against Brucella infections. Priming of Cynomolgus philipinensis with purified antigen of Brucella melitensis prior to injection of Rev. I vaccine. J Comp Pathol 1973;83(July (3)):357-67.
56. Ragan VE. The Animal and Plant Health Inspection Service (APHIS) brucellosis eradication program in the United States. Vet Microbiol 2002;90(December (1-4)):11-8.
57. Montes J, Rodriguez MA, Martin T, Martin F. Laboratory-acquired meningitis caused by Brucella abortus strain 19. J Infect Dis 1986;154(November (5)):915-6.
58. Bardenwerper HW. Human sickness caused by Brucella abortus, Strain 19. JAMA 1954;155:970-1.
59. Meyer ME. Characterization of Brucella abortus Strain 19 isolated from human and bovine tissues and fluids. Am J Vet Res 1985;46:902-4.
60. Andrew H, Love J, Leahy PN, Miller A. Letter: Contracting brucellosis from S19 vaccine. Vet Rec 1973;93(September (13)):380.
61. Bosseray N, Plommet M. Brucella suis S2, Brucella melitensis Rev. 1 and Brucella abortus S19 living vaccines: residual virulence and immunity induced against three Brucella species challenge strains in mice. Vaccine 1990;8:462-8.
62. Campos E, Cravero SL, Delgui L, Mora I, Kahn N, Arese AI, et al. Brucella abortus INTA2, a novel strain 19 (Delta)bp26::luc (Delta)bmp18 double mutant lacking drug resistance markers. Vet Microbiol 2002;87(June 1):1-13.
63. Stevens MG, Olsen SC, Pugh GWJ, Palmer MV. Immune and pathologic responses in mice infected with Brucella abortus 19, RB51, or 2308. Infect Immun 1994;62:3206-12.
64. Robertson GT, Elzer PH, Roop 2nd RM. In vitro and in vivo phenotypes resulting from deletion of the high temperature requirement A (htrA) gene from the bovine vaccine strain Brucella abortus S19. Vet Microbiol 1996;49(3-4): 197-207.
65. Bandyopadhyay S, Sasmal D, Dutta TK, Ghosh MK, Sarkar M, Sasmal NK, et al. Seroprevalence of brucellosis in yaks (Poephagus grunniens) in India and evaluation of protective immunity to S19 vaccine. Trop Anim Health Prod 2009;41(4):587-92.
66. Stuart JE, Bills CB, DeMattel JD, Mace DL. The results of eleven years' vaccinating with Strain 19. Proc Annu Meet US Livestock Sanit Assoc 1959;63:83-90.
67. Lawson JR. Strain 19 and the control of brucellosis. Vet Rec 1950;62:823-30.
68. Millar R. Brucella abortus infection in the horse. Br Vet J 1961;117:167-70.
69. Golosov IM, Klimontov MI, Zabrodin VA. Results of reindeer vaccination with Brucella abortus strain 19. Veterinariia 1964;41:29-31.
70. Nicoletti P. Vaccination of cattle with Brucella abortus strain 19 administered by differing routes and doses. Vaccine 1984;2(2):133-5.
71. Nicoletti P, Milward FW. Protection by oral administration of Brucella abortus strain 19 against an oral challenge exposure with a pathogenic strain of Brucella. Am J Vet Res 1983;44(9):1641-3.
72. Lord VR, Schurig GG, Cherwonogrodzky JW, Marcano MJ, Melendez GE. Field study of vaccination of cattle with Brucella abortus strains RB51 and 19 under high and low disease prevalence. Am J Vet Res 1998;59(8):1016-20.
73. Crawford RP, Adams LG, Ficht TA, Templeton JW, Williams JD. Effect of stage of gestation on efficacy of Brucella abortus strain-19 vaccination in cattle. Am J Vet Res 1991;52(11):1848-51.
74. Crawford RP, Adams LG, Ficht TA, Williams JD. Effects of stage of gestation and breed on bovine responses to vaccination with Brucella abortus strain 19. J Am Vet Med Assoc 1991;199(October (7)):887-91.
75. Davis DS, Templeton JW, Ficht TA, Huber JD, Angus RD, Adams LG. Brucella abortus in Bison. II. Evaluation of strain 19 vaccination of pregnant cows. JWildl Dis 1991;27(2):258-64.
76. AbuDamir H, TageldinMH, Kenyon SJ, Idris OF. Isolation of Brucella abortus from experimentally infected dromedary camels in Sudan: a preliminary report. Vet Res Commun 1989;13(6):403-6.
77. Schuurman HJ. The serological response of adult cattle to vaccination with reduced dose Brucella abortus S19, a trial under Zambian conditions. Vet Q 1983;5(2):94-6.
78. Comerci DJ, Pollevick GD, Vigliocco AM, Frasch AC, Ugalde RA. Vector development for the expression of foreign proteins in the vaccine strain Brucella abortus S19. Infect Immun 1998;66(8):3862-6.
79. Boschiroli ML, Cravero SL, Arese AI, Campos E, Rossetti OL. Protection against infection in mice vaccinated with a Brucella abortus mutant. Infect Immun 1997;65(2):798-800.
80. Elzer PH, Smith J, Roffe T, Kreeger T, Edwards J, Davis D. Evaluation of Brucella abortus strain RB51 and strain 19 in pronghorn antelope. Ann NY Acad Sci 2002;969:102-5.
81. Arenas-Gamboa AM, Ficht TA, Kahl-McDonagh MM, Gomez G, Rice-Ficht AC. The Brucella abortus S19 DeltavjbR live vaccine candidate is safer than S19 and confers protection against wild-type challenge in BALB/c mice when delivered in a sustained-release vehicle. Infect Immun 2009;77(2):877-84.
82. Spink WW, Thompson H. Human brucellosis caused by Brucella abortus, strain 19. JAMA 1953;153:1162-5.
83. Crasta OR, Folkerts O, Fei Z, Mane SP, Evans C, Martino-Catt S, et al. Genome sequence of Brucella abortus vaccine strain S19 compared to virulent strains yields candidate virulence genes. PLoS ONE 2008;3(January (5)): e2193.
84. Kahl-McDonagh MM, Ficht TA. Evaluation of protection afforded by Brucella abortus and Brucella melitensis unmarked deletion mutants exhibiting different rates of clearance in BALB/c mice. Infect Immun 2006;74(7):4048-57.
85. Winter AJ, Schurig GG, Boyle SM, Sriranganathan N, Bevins JS, Enright FM, et al. Protection of BALB/c mice against homologous and heterologous species of Brucella by rough strain vaccines derived from Brucella melitensis and Brucella suis biovar 4. Am J Vet Res 1996;57:677-83.
86. Monreal D, Grillo MJ, Gonzalez D, Marin CM, De Miguel MJ, Lopez-Goni I, et al. Characterization of Brucella abortus O-polysaccharide and core lipopolysaccharide mutants and demonstration that a complete core is required for rough vaccines to be efficient against Brucella abortus and Brucella ovis in the mouse model. Infect Immun 2003;71(6):3261-71.
87. Spink WW, Hall JW, Finstad J, Mallet E. Immunization with live Brucella organisms: results of safety test in humans. Bull WHO 1962;26:409-20.